
Third Rock Ventures Launches Fulcrum Therapeutics with \$55M Series A Investment

JULY 22, 2016

Third Rock Ventures, LLC announced the launch of Fulcrum Therapeutics, a company focused on unlocking gene control mechanisms to develop small molecule therapies. Fulcrum will discover and develop small molecules that modulate the on/off control mechanisms that regulate genes.

Fulcrum was established with \$55 million in Series A financing to further develop a cross-disciplinary product engine to identify and modulate gene regulatory targets core to disease. Through its product engine, Fulcrum will develop a robust pipeline across therapeutic areas, spearheaded by two initial programs in genetic diseases.

The WilmerHale team on the deal was led by Partner [Lia Der Marderosian](#), Senior Associate [Stephanie Singer](#) and Associate Byron Crowe.

Read the [Fulcrum Therapeutics press release](#) for more information.